TickerFacts.

Greenland Mines Ltd (GRML): Cash & Equivalents

Annual figures by period end, from SEC filings.

$7.18M
As of 2025-12-31
$9.30M
As of 2026-06-30
+176.1%
3-year compound annual growth
2022-12-31: $341.0K2023-12-31: $2.8K2024-12-31: $63.7K2025-12-31: $7.18M$7.18M
2022-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$7.18Mn/m2026-08-14, Balance as of period end
2024-12-31$63.7Kn/m2026-08-14, Balance as of period end
2023-12-31$2.8K-99.2%2025-03-31, Balance as of period end
2022-12-31$341.0Kn/a2024-04-17, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Greenland Mines Ltd (GRML)2025-12-31$7.18Mn/m
Dyadic International Inc (DYAI)2025-12-31$4.62M-29.0%
Calidi Biotherapeutics, Inc. (CLDI)2024-12-31$9.60Mn/a
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$1.66M-15.4%
VivoSim Labs, Inc. (VIVS)2026-03-31$5.02M-55.6%
Silexion Therapeutics Corp (SLXN)2025-12-31$5.99M+404.7%
BioAtla, Inc. (BCAB)2025-12-31$7.12M-85.5%
Intensity Therapeutics, Inc. (INTS)2025-12-31$11.92M+360.3%
MiNK Therapeutics, Inc. (INKT)2025-12-31$13.36M+191.9%

Compare GRML, DYAI, CLDI, SCNI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗